An Australian private member's bill which proposes a ban on the patenting of human genes and biological materials will have ramifications not just for the local R&D industries. It could change the way the country is viewed as a place for inward investment.
An Australian private member's bill which proposes a ban on the patenting of human genes and biological materials will have ramifications not just for the local R&D industries. It could change the way the country is viewed as a place for inward investment.
Dr Anna Lavelle, chief executive officer of AusBiotech, who has been lobbying parliamentarians hard over the last few weeks to...
Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.
The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.
As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.
Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.
After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.
Swiss major confident that new oncology drugs will fill revenue gap.
